Results 41 to 50 of about 384,579 (350)

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.

Journal of the American Medical Association (JAMA), 2020
Importance A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. Objective To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China.
S. Xia, Kai Duan, Yuntao Zhang, Dongyang Zhao, Huajun Zhang, Z. Xie, Xinguo Li, Cheng Peng, Yan-Bo Zhang, Wei Zhang, Y. Yang, Wei Chen, Xiaoxiao Gao, W. You, Xuewei Wang, Zejun Wang, Zhengli Shi, Yanxia Wang, Xuqin Yang, Lianghao Zhang, Lili Huang, Qian Wang, Jia Lu, Yongli Yang, Jing Guo, Wei Zhou, X. Wan, Cong Wu, Wenhui Wang, Shihe Huang, Jianhui Du, Z. Meng, A. Pan, Zhiming Yuan, S. Shen, Wanshen Guo, Xiaoming Yang   +36 more
semanticscholar   +1 more source

Impact of lipid nanoparticle size on mRNA vaccine immunogenicity.

Journal of Controlled Release, 2021
Lipid nanoparticles (LNP) are effective delivery vehicles for messenger RNA (mRNA) and have shown promise for vaccine applications. Yet there are no published reports detailing how LNP biophysical properties can impact vaccine performance.
Kimberly J. Hassett, Jaclyn Higgins, Angela Woods, B. Levy, Yan Xia, C. Hsiao, Edward Acosta, Ö. Almarsson, M. Moore, Luis A. Brito   +9 more
semanticscholar   +1 more source

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
Machera, Francisca, Abdulla, Salim, Tanner, M., Schellenberg David, Vekemans, J., Richard Kamata, Kamata, Richard, Grace Mwangoka, Kubhoja, S., Leach, Amanda, Villafana Tonya, Dubois Marie-Claude, Sulende Kubhoja, Carter, T, Carter Terrell, Villafana, T, Dubois, M-C, Salim Nahya, Mshinda, H, Dubois, Marie-Claude, Leach, A, Joe Cohen, Salim, N, Kubhoja, Sulende, Vekemans Johan, Salim Abdulla, Mwangoka, G, Carter, T., Juma, O., Mohammed, A., Marcel Tanner, Marie-Claude Dubois, Mshinda Hassan, Marc Lievens, Aebi, Thomas, Kamata, R., Nahya Salim, Ballou, W Ripley, Machera, F., Leach, A., Lievens, Marc, Mohammed Ali, Leach Amanda, Ballou, W. R., W Ripley Ballou, Abdulla, S, Amanda Leach, Kubhoja Sulende, Cohen Joe, Ali Mohammed, Mwangoka Grace, Lievens Marc, Salim, N., Cohen, J., Hassan Mshinda, Abdulla, S., Mohammed, A, Aebi, T, Shomari, M, Mwangoka, G., Schellenberg, D, Cohen, Joe, Schellenberg, D., Machera Francisca, Tanner Marcel, Abdulla Salim, Tanner, M, Carter, Terrell, Juma, Omar, Ballou W Ripley, Omar Juma, Machera, F, Shomari, Mwanajaa, Aebi, T., Schellenberg, David, Mwanajaa Shomari, Lievens, M, Cohen, J, Thomas Aebi, Lievens, M., Juma Omar, Vekemans, J, Juma, O, Vekemans, Johan, Mshinda, Hassan, Tanner, Marcel, Shomari Mwanajaa, Mwangoka, Grace, David Schellenberg, Francisca Machera, Villafana, T., Shomari, M., Mshinda, H., Terrell Carter, Salim, Nahya, Mohammed, Ali, Dubois, M. C., Ballou, WR, Tonya Villafana, Kamata Richard, Kubhoja, S, Aebi Thomas, Johan Vekemans, Kamata, R, Villafana, Tonya   +104 more
core   +1 more source

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Nature Medicine, 2021
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
T. Schmidt, V. Klemis, D. Schub, J. Mihm, F. Hielscher, Stefanie Marx, A. Abu-Omar, L. Ziegler, C. Guckelmus, R. Urschel, S. Schneitler, S. Becker, B. Gärtner, U. Sester, M. Sester   +14 more
semanticscholar   +1 more source

Taking immunogenicity assessment of therapeutic proteins to the next level [PDF]

, 2011
Therapeutic proteins provide innovative and effective therapies for numerous diseases. However, some of these products are associated with unwanted immunogenicity that may lead to clinical consequences such as reduced or loss of efficacy, altered ...
Mire-Sluis, A, Subramanyam, M., T. Platts-Mills, Stas, P., Krause, R, Reipert, BM, R. Krause, Trouvin, JH, J. Windisch, Jefferis, R., D. Kramer, Schellekens, H., Thorpe, R, F. Ehmann, Lubiniecki, A., Buttel, I.C., P. Chamberlain, Sub Biotechnological drugs, Platts-Mills, T, Kramer, D, R. Seitz, Weise, M., Stas, P, Ragheb, J.A., Chowers, Y, P. Stas, Windisch, J., Kramer, D., Schneider, CK, Greinacher, A., Lloyd, P, A. Greinacher, Windisch, J, J.A. Ragheb, Ehmann, F., Seitz, R., R. Jefferis, Reipert, B.M., A. Mire-Sluis, Pharmaceutics, H. Schellekens, M. Weise, Buettel, IC, Chowers, Y., C.K. Schneider, Ragheb, JA, Greinacher, A, Kropshofer, H, M. Subramanyam, Schneider, C.K., Lubiniecki, A, Mire-Sluis, A., J.-H. Trouvin, H. Kropshofer, Innovation Studies, R. Thorpe, Kropshofer, H., Lloyd, P., Seitz, R, Ehmann, F, P. Lloyd, Subramanyam, M, Weise, M, Y. Chowers, Jefferis, Royston, Thorpe, R., A. Lubiniecki, Chamberlain, P., Krause, R., I.C. Büttel, Trouvin, J.H., B.M. Reipert, Platts-Mills, T., Chamberlain, P, Schellekens, H   +74 more
core   +1 more source

Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo [PDF]

, 2004
Strategies to enhance the immunogenicity of tumors are urgently needed. Although vaccination with irradiated dying lymphoma cells recruits a tumor-specific immune response, its efficiency as immunogen is poor.
Zimmermann, VS, Voll, Reinhard E., Turnay, Javier, Manfredi, Angelo A., Turnay, J, Dumitriu, IE, Voll, RE, Zimmermann, Valérie S, Angelo A. Manfredi, Bertling, Wolf, Rovere-Querini, P, Kalden, JR, Udo S. Gaipl, Herrmann, M, Attilio Bondanza, Gaipl, Udo S, Wolf Bertling, Bertling, W, Patrizia Rovere-Querini, Ingrid E. Dumitriu, Bondanza, Attilio, Stach, Christian M., Pöschl, E, Stach, Christian M, Gaipl, US, Javier Turnay, Herrmann, Martin, Martin Herrmann, Dumitriu, Ingrid E., Rovere-Querini, Patrizia, Christian M. Stach, Manfredi, Angelo A, Kalden, Joachim R, Valérie S. Zimmermann, Pöschl, Ernst, Stach, CM, Dumitriu, Ingrid E; id_orcid, Gaipl, Udo S., Joachim R. Kalden, Bondanza, A, Zimmermann, Valérie S., Voll, Reinhard E, Kalden, Joachim R., Reinhard E. Voll, Manfredi, AA, Ernst Pöschl   +45 more
core   +1 more source

Predicting Immunogenicity Risk in Biopharmaceuticals [PDF]

, 2021
The assessment of immunogenicity of biopharmaceuticals is a crucial step in the process of their development. Immunogenicity is related to the activation of adaptive immunity.
Irini Doytchinova, Ivan Dimitrov, Nikolet Doneva   +2 more
core   +1 more source

Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]

PLoS Computational Biology, 2013
T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis, Matt Maybeno, Jason A Greenbaum, Daniela Weiskopf, Aruna D De Silva, Alessandro Sette, Can Keşmir, Bjoern Peters   +7 more
doaj   +1 more source

AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer

Molecular Therapy, 2020
Gene therapy with adeno-associated virus (AAV) vectors has demonstrated safety and long-term efficacy in a number of trials across target organs, including eye, liver, skeletal muscle, and the central nervous system.
Helena Costa Verdera, K. Kuranda, F. Mingozzi   +2 more
semanticscholar   +1 more source

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers [PDF]

, 2011
10.08.12 KB OA publisher, published version ok to add to Spiral.
Schmidt, C, Lorna Clark, Arlene Hurley, Kopycinski Jakub T., David D. Ho, Caskey, M, Clark, L, Hannaman, D, Gilmour Jill, Schlesinger, SJ, Cheeseman Hannah, Hurley Arlene, Smith Carol, Hurley, A, Ho, DD, Cheeseman, H, Ho David D., Caskey Marina, Fast Patricia, Dally, L, Marina Caskey, Gill Dilbinder K., Roselle Vittorino, Vasan, S, Sarah J Schlesinger, Andersen, J, Harriet H Park, Patricia Fast, Bernard Robert, Clark Lorna, Vittorino, R, Gardiner David F., Josephine H Cox, Dilbinder K. Gill, Dally Len, Robert Bernard, Vasan Sandhya, Josephine H. Cox, Jill Gilmour, Claudia Schmidt, Andersen Johanne, Johanne Andersen, Jakub T Kopycinski, Park Harriet H., Cox, JH, Smith, C, David F Gardiner, Gilmour, J, Harriet H. Park, Tony Tarragona-Fiol, Huang Yaoxing, Sarah J. Schlesinger, Len Dally, Gill, DK, Dilbinder K Gill, Cox Josephine H., Bernard, R, Boente-Carrera, M, Boente-Carrera Mar, Hannah Cheeseman, Sandhya Vasan, Carol Smith, Schlesinger Sarah J., Fast, P, Park, HH, Drew Hannaman, Schmidt Claudia, Tarragona-Fiol, T, Kopycinski, JT, Jakub T. Kopycinski, Huang, Y, Mar Boente-Carrera, Gardiner, DF, Yaoxing Huang, Hannaman Drew, Tarragona-Fiol Tony, Dugin, DP, Daniel P. Dugin, Daniel P Dugin, Vittorino Roselle, Dugin Daniel P., David D Ho, David F. Gardiner   +82 more
core   +1 more source